H
Hagen F. Kennecke
Researcher at BC Cancer Agency
Publications - 138
Citations - 6211
Hagen F. Kennecke is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 31, co-authored 122 publications receiving 5342 citations. Previous affiliations of Hagen F. Kennecke include Virginia Mason Medical Center & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Metastatic Behavior of Breast Cancer Subtypes
Hagen F. Kennecke,Rinat Yerushalmi,Ryan Woods,Maggie C.U. Cheang,David Voduc,Caroline Speers,Torsten O. Nielsen,Karen A. Gelmon +7 more
TL;DR: Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse, and luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.
Journal ArticleDOI
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc,Maggie C.U. Cheang,Scott Tyldesley,Karen A. Gelmon,Torsten O. Nielsen,Hagen F. Kennecke +5 more
TL;DR: Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.
Journal ArticleDOI
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan Ellard,Mark Clemons,Karen A. Gelmon,B. Norris,Hagen F. Kennecke,Stephen Chia,Kathleen I. Pritchard,Andrea Eisen,T. Vandenberg,Marianne Taylor,Eric Sauerbrei,Moshe Mishaeli,David G. Huntsman,Wendy Walsh,Martin Olivo,L. McIntosh,Lesley Seymour +16 more
TL;DR: Oral everolimus has activity in metastatic breast cancer that is schedule dependent and no biologic correlates of response could be identified, although there were trends favoring benefit in ER-positive and HER2-negative metastatic Breast cancer.
Journal ArticleDOI
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John F.R. Robertson,Jean-Marc Ferrero,H Bourgeois,Hagen F. Kennecke,Richard De Boer,William Jacot,Jesse McGreivy,Samuel Suzuki,Min Zhu,Ian McCaffery,Elwyn Loh,Jennifer Gansert,Peter A. Kaufman +12 more
TL;DR: Addition of ganitumab to endocrine treatment in women with previously treated hormone-receptor-positive locally advanced or metastatic breast cancer did not improve outcomes and results do not support further study of gansitumAB in this subgroup of patients.
Journal ArticleDOI
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Arvind Dasari,Van K. Morris,Carmen J. Allegra,Chloe E. Atreya,Al B. Benson,Patrick McKay Boland,Ki Y. Chung,Mehmet Sitki Copur,Ryan B. Corcoran,Dustin A. Deming,Andrea Dwyer,Maximilian Diehn,Cathy Eng,Thomas J. George,Marc J. Gollub,Rachel Anne Goodwin,Stanley R. Hamilton,Jaclyn F. Hechtman,Howard S. Hochster,Theodore S. Hong,Federico Innocenti,Atif Iqbal,Samuel A. Jacobs,Hagen F. Kennecke,James J. Lee,Christopher H. Lieu,Heinz-Josef Lenz,O. Wolf Lindwasser,C. Montagut,Bruno C. Odisio,Fang-Shu Ou,Laura S. Porter,Kanwal Pratap Singh Raghav,Deborah Schrag,Aaron Scott,Qian Shi,John H. Strickler,Alan P. Venook,Rona Yaeger,Greg Yothers,Y. Nancy You,Jason A. Zell,Scott Kopetz +42 more
TL;DR: The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments.